These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16890020)

  • 1. Drug delivery to the upper small intestine window using gastroretentive technologies.
    Streubel A; Siepmann J; Bodmeier R
    Curr Opin Pharmacol; 2006 Oct; 6(5):501-8. PubMed ID: 16890020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gastroretentive dosage forms].
    Kiss D; Zelkó R
    Acta Pharm Hung; 2005; 75(3):169-76. PubMed ID: 16318241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroretentive dosage forms.
    Moës AJ
    Crit Rev Ther Drug Carrier Syst; 1993; 10(2):143-95. PubMed ID: 8370085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroretentive drug delivery systems.
    Streubel A; Siepmann J; Bodmeier R
    Expert Opin Drug Deliv; 2006 Mar; 3(2):217-33. PubMed ID: 16506949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroretentive microparticles for drug delivery applications.
    Adebisi A; Conway BR
    J Microencapsul; 2011; 28(8):689-708. PubMed ID: 21726124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview on Various Approaches and Recent Patents on Gastroretentive Drug Delivery Systems.
    Kumar M; Kaushik D
    Recent Pat Drug Deliv Formul; 2018; 12(2):84-92. PubMed ID: 29521255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview on gastroretentive drug delivery systems for improving drug bioavailability.
    Lopes CM; Bettencourt C; Rossi A; Buttini F; Barata P
    Int J Pharm; 2016 Aug; 510(1):144-58. PubMed ID: 27173823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastroretentive floating drug-delivery systems: a critical review.
    Kotreka UK; Adeyeye MC
    Crit Rev Ther Drug Carrier Syst; 2011; 28(1):47-99. PubMed ID: 21395515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation strategies for absorption windows.
    Davis SS
    Drug Discov Today; 2005 Feb; 10(4):249-57. PubMed ID: 15708743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroretentive dosage forms: overview and special case of Helicobacter pylori.
    Bardonnet PL; Faivre V; Pugh WJ; Piffaretti JC; Falson F
    J Control Release; 2006 Mar; 111(1-2):1-18. PubMed ID: 16403588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model.
    Kagan L; Hoffman A
    Eur J Pharm Biopharm; 2008 May; 69(1):238-46. PubMed ID: 18068342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Gas Empowered Drug Delivery system for peptide delivery in the small intestine.
    Sadeghi AM; Avadi MR; Ejtemaimehr Sh; Abashzadeh Sh; Partoazar A; Dorkoosh F; Faghihi M; Rafiee-Tehrani M; Junginger HE
    J Control Release; 2009 Feb; 134(1):11-7. PubMed ID: 19014985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Oral controlled release dosage forms].
    Mehuys E; Vervaet C
    J Pharm Belg; 2010 Jun; (2):34-8. PubMed ID: 20623984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications.
    Vrettos NN; Roberts CJ; Zhu Z
    Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Floating microspheres: to prolong the gastric retention time in stomach.
    Bhadouriya P; Kumar M; Pathak K
    Curr Drug Deliv; 2012 May; 9(3):315-24. PubMed ID: 22023206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
    Miyazaki Y; Yakou S; Takayama K
    J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastric retentive drug-delivery systems.
    Hwang SJ; Park H; Park K
    Crit Rev Ther Drug Carrier Syst; 1998; 15(3):243-84. PubMed ID: 9699081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms.
    Hoffman A; Stepensky D; Lavy E; Eyal S; Klausner E; Friedman M
    Int J Pharm; 2004 Jun; 277(1-2):141-53. PubMed ID: 15158977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.
    Sarparanta MP; Bimbo LM; Mäkilä EM; Salonen JJ; Laaksonen PH; Helariutta AM; Linder MB; Hirvonen JT; Laaksonen TJ; Santos HA; Airaksinen AJ
    Biomaterials; 2012 Apr; 33(11):3353-62. PubMed ID: 22285465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.